Intellia Therapeutics (NTLA) Cash from Investing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Investing Activities data on file, last reported at $66.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 29.7% year-over-year to $66.3 million in Q1 2026; TTM through Mar 2026 was $200.0 million, a 6.53% decrease from a year earlier, with the FY2025 full-year figure at $228.0 million, up 81.6% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $66.3 million, up from $27.5 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for NTLA reached as high as $151.6 million in Q4 2024 and fell as low as -$122.2 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged $32.3 million across 5 years, with a median of $45.9 million in 2023.
• Across the five-year window, Cash from Investing Activities tumbled 357.51% in 2023 and soared 1498.51% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$30.2 million in 2022, then jumped by 252.36% to $45.9 million in 2023, then jumped by 229.93% to $151.6 million in 2024, then sank by 81.83% to $27.5 million in 2025, then soared by 140.83% to $66.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $66.3 million in Q1 2026, $27.5 million in Q4 2025, and -$741000.0 in Q3 2025.